Get to know our clinical trials
Phase I study to evaluate the safety and tolerability of GS-4528 in monotherapy and in combination with an anti-PD-1 monoclonal antibody in adults with advanced solid tumors.
EL OBJETIVO ES ANALIZAR UN NUEVO FÁRMACO EN INVESTIGACIÓN LLAMADO GS-4528 EN MONOTERAPIA Y EN COMBINACIÓN CON ZIMBERELIMAB (ZIM) EN SERES HUMANOS PARA COMPROBAR SI ES SEGURO Y TOLERABLE EN EL TRATAMIENTO DE PACIENTES CON DIFERENTES TIPOS DE CÁNCER
Technical Summary
- ESTUDIO DE FASE I PARA EVALUAR LA SEGURIDAD Y TOLERABILIDAD DE GS-4528 EN MONOTERAPIA Y EN COMBINACIÓN CON UN ANTICUERPO MONOCLONAL ANTIPD-1 EN ADULTOS CON TUMORES SÓLIDOS AVANZADOS
- Code EudraCT: .
- Protocol number: GS-US-616-6291
- Promoter: Gilead Science
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.